Comparative Pharmacology
Head-to-head clinical analysis: CROMOLYN SODIUM versus GASTROCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROMOLYN SODIUM versus GASTROCROM.
CROMOLYN SODIUM vs GASTROCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes mast cell membranes, inhibiting release of histamine and other mediators of inflammation.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
For bronchial asthma: 20 mg (2 capsules) orally 4 times daily, administered 1 hour before meals and at bedtime. For allergic rhinitis: 1 spray (5.2 mg) in each nostril 3-6 times daily. For mastocytosis: 200 mg orally 4 times daily.
200 mg orally four times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours for the absorbed fraction; the short half-life necessitates frequent dosing (e.g., 4 times daily) for sustained clinical effect.
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Primarily excreted unchanged in bile and feces (approximately 98% after oral administration); renal excretion is minimal (<1% unchanged in urine). After inhalation, a small amount is absorbed systemically and similarly excreted via bile/feces.
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Category A/B
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer